British medical journal The Lancet has published a study on the effects of India’s indigenous vaccine, Bharat Biotech’s Covaxin and said that the vaccine doses are well tolerated with no vaccine-related serious adverse events found.
The Drug Controller General of India had granted restricted emergency use authorisation to Bharat Biotech’s Covaxin under the clinical trials mode where consent was required from beneficiaries before vaccination. Bharat Biotech successfully administered the dose of its COVID-19 vaccine, Covaxin, to 13,000 people.
BBV152 (also known as Covaxin) is a whole-virion inactivated SARS-CoV-2 vaccine. The double–blind, multicentre, randomized, controlled trials were conducted in 11 hospitals across India.
